mRNA has moved from a research tool to a platform for vaccines, protein replacement, gene editing and cell engineering. Whatever the application, the molecule is made the same way: a DNA template is transcribed in vitro, capped, purified, and then delivered into cells.

Each step shapes the next. A template that is not fully linearized, a polymerase that generates double-stranded RNA, or a cap that is not Cap1 may not look like a problem on the day, but it shows up later as low yield, immune activation or weak protein expression. This guide walks through the full workflow, the decisions to make at each stage, and how to troubleshoot when results fall short.

Key takeaways

• IVT makes mRNA from a linearized DNA template using T7 RNA polymerase, nucleotides and supporting enzymes. Template quality sets the ceiling for everything downstream.

• Double-stranded RNA (dsRNA) byproducts are a major source of unwanted innate immune activation. Polymerase choice, reaction conditions and purification all influence them.

• A Cap1 structure supports translation and helps mRNA avoid innate immune sensing. It can be built co-transcriptionally or enzymatically.

• Modified nucleotides such as pseudouridine and N1-methylpseudouridine are widely used to reduce immunogenicity and support translation.

• Choose the LNP to match the application: in vitro, primary cells, systemic in vivo, or tissue-targeted delivery such as lung.

The mRNA workflow at a glance

Stage	What happens	Key decisions	Related HZYMES products
1. Template	A DNA template with a T7 promoter, UTRs, open reading frame and poly(A) is linearized	Cut site, enzyme type, completeness of digestion	BsaI, BspQI
2. Transcription	T7 RNA polymerase copies the template into RNA	Polymerase type, nucleotide modification, reagent format	T7 RNA Polymerase (standard, Low dsRNA, Thermostable), NTPs, Pseudo-UTP, N1-Me-Pseudo-UTP, Hi-yield IVT reagents, RNase Inhibitor, Pyrophosphatase, DNase I
3. Capping	A 5′ cap is added during or after transcription	Co-transcriptional vs enzymatic capping; Cap0 vs Cap1	Co-capping reagents, cap analogs (GAG 3′OH, GAG 3′OMe, GAU), Cap1 capping system, Vaccinia Capping Enzyme, Cap2′-O-Methyltransferase, SAM
4. Purification and QC	Enzymes, template DNA, free nucleotides and byproducts are removed; the product is characterized	Purification method, QC panel	(Method-dependent)
5. Delivery	mRNA is formulated into lipid nanoparticles or transfected	LNP type for the target cell or tissue	Fast LNP (in vivo, in vitro, primary cell, lung-targeted)
6. Validation	Expression or function is confirmed with control and functional mRNAs	Reporter vs functional readout	Research and functional mRNAs (modified and unmodified), saRNA

Stage 1: DNA template preparation

IVT starts with a DNA template that carries a T7 promoter followed by the mRNA sequence: 5′ UTR, open reading frame, 3′ UTR and a poly(A) tail. Templates are usually plasmids linearized just after the poly(A) region, or PCR products.

Why complete linearization matters

If a plasmid is not cut, or is cut incompletely, T7 polymerase can continue around the plasmid and produce longer, heterogeneous transcripts. Complete digestion gives defined run-off transcripts of the intended length, which keeps the product uniform from batch to batch.

Choosing a restriction enzyme

Type IIS enzymes such as BsaI and BspQI cut outside their recognition sequences. This lets you design the template so that it ends exactly at the end of the poly(A) tail, without extra bases left behind by a recognition site. A short checklist:

• Confirm the recognition site occurs only once in the plasmid, at the intended position.

• Digest to completion and verify on a gel before starting IVT.

• Purify the linearized template to remove enzyme, salts and any RNase contamination.

• Quantify accurately, since template amount affects yield and consistency.

Stage 2: In vitro transcription

A standard IVT reaction contains the linear template, T7 RNA polymerase, four nucleotide triphosphates (ATP, GTP, CTP and UTP or a modified UTP), a buffer containing magnesium, an RNase inhibitor and inorganic pyrophosphatase. Reactions typically run at 37 °C for one to several hours.

The supporting enzymes

• Inorganic pyrophosphatase breaks down pyrophosphate, a byproduct of transcription that can precipitate with magnesium and limit yield.

• RNase inhibitor protects the RNA product from trace RNase contamination.

• DNase I is added after transcription to degrade the DNA template.

Choosing a T7 RNA polymerase

Polymerase	Best suited for	HZYMES data
T7 RNA Polymerase (Cat. No. HBP000330)	High-yield and large-scale production, long templates such as saRNA, and templates that are hard to transcribe	Engineered M6 variant with about 3.8-fold higher specific activity (U/mg) than wild-type, over 10-fold higher solution activity (U/mL) thanks to improved oxidative stability, and lower dsRNA content than wild-type
T7 RNA Polymerase (low dsRNA) (Cat. No. HBP000340)	Applications where innate immune activation matters, such as personalized cancer vaccines, gene editing, protein replacement therapy, and in vivo or primary cell work	dsRNA typically reduced by more than 10-fold at standard 37 °C conditions, with no change to existing IVT parameters. In HZYMES testing, mRNA made with it gave lower IFN-α and IL-6 levels in transfected RAW cells
T7 RNA Polymerase (thermostable) (Cat. No. HBP000350)	High-temperature IVT, templates with strong secondary structure or GC-rich regions, and circRNA precursor production	Directed-evolution mutant with a 270-fold longer half-life and 58-fold higher activity than wild-type at 52 °C. It also stays active at 37 °C, so it can replace wild-type without process redesign

All three polymerases are supplied at 50 U/µL. They are produced and quality-controlled under GMP-compliant procedures with traceability of the production process and all raw and auxiliary materials. Production is animal-origin free and uses no ampicillin or other β-lactam antibiotics, and residual endonuclease, exonuclease, nickase, RNase and endotoxin are controlled. Transport below 0 °C and store at −25 to −15 °C.

Why dsRNA matters

T7 polymerase can produce dsRNA byproducts, for example through the 3′ extension of transcripts or the generation of antisense RNA. Cells have sensors such as RIG-I, MDA5 and PKR that recognize dsRNA and trigger innate immune responses, which can reduce protein expression and cause unwanted inflammation. For in vivo and primary cell work, controlling dsRNA is one of the most important quality goals of the IVT step.

Modified nucleotides

Replacing uridine with pseudouridine (Pseudo-UTP) or N1-methylpseudouridine (N1-Me-Pseudo-UTP) reduces recognition by innate immune sensors and can improve translation. N1-methylpseudouridine is used in the approved COVID-19 mRNA vaccines and is now a common default for therapeutic-oriented work. Fully substituting UTP is the usual approach; confirm that your polymerase and reaction conditions perform well with the modified nucleotide.

Ready-to-use IVT reagents

Premixed IVT reagents reduce pipetting steps and variability. HZYMES offers Hi-yield IVT reagents in N1-Me-pUTP, pUTP, Low dsRNA and Thermostable formats, as well as co-capping reagents that combine transcription and capping in one reaction.

Stage 3: Capping

The 5′ cap protects mRNA from degradation, supports efficient translation and helps the cell recognize the RNA as its own. A Cap0 structure carries an N7-methylated guanosine. Cap1 adds a 2′-O-methyl group on the first transcribed nucleotide, which reduces recognition by innate immune sensors such as IFIT1. For most therapeutic-oriented work, Cap1 is the target.

Two routes to a capped mRNA

	Co-transcriptional capping	Enzymatic capping
How it works	A cap analog is added to the IVT reaction and incorporated at the start of transcription	After IVT, Vaccinia Capping Enzyme and SAM add the cap; Cap2′-O-Methyltransferase then converts Cap0 to Cap1
Workflow	One reaction; fewer steps	Extra reaction and cleanup step after transcription. HZYMES enzymes do not require a mandatory pre-denaturation step
Cap1 outcome	Direct, with the Cap GAG-based co-capping reagents	Achieved with the methyltransferase step
Template requirement	The template start sequence must match the cap analog. HZYMES co-capping reagents use a T7 promoter followed by an AG initiation sequence	Flexible; any uncapped RNA can be capped
Good fit when	You want speed and simplicity, or a standardized one-pot process	You need flexibility in the start sequence or want to cap RNA made separately

HZYMES supplies both routes: cap analogs (GAG 3′OH, GAG 3′OMe and GAU), co-capping IVT reagents, the Cap1 capping system, Vaccinia Capping Enzyme, Cap2′-O-Methyltransferase and SAM.

HZYMES capping data at a glance

Product	Key data
Co-capping T7 IVT reagents (Cat. Nos. HBP001507 to HBP001510)	Natural Cap-1 mRNA in a single co-transcriptional reaction, from a template with a T7 promoter and AG initiation sequence. Available with pUTP or N1-Me-pUTP, and with Cap GAG or Cap GAG (3′OMe). Built on an engineered high-specific-activity T7 mutant. 50T packs
Cap analogs: Cap GAG (3′OH), Cap GAG (3′OMe), Cap GAU	Purity above 98%. GMP-compliant, animal-origin-free production with ultra-low metal residue control. DMF filing support available. Transport below 0 °C, store at −25 to −15 °C
Vaccinia Capping Enzyme (Cat. No. HBP000606)	Above 95% capping efficiency for standard mRNA sequences, with comparable efficiency with or without 65 °C pre-denaturation. 10 U/µL
mRNA Cap2′-O-Methyltransferase (Cat. No. HBP000701)	Converts Cap 0 to Cap 1. Above 95% capping efficiency for standard sequences, and compatible with a pre-denaturation-free workflow. 50 U/µL
S-adenosylmethionine (SAM)	Methyl donor for enzymatic capping. Purity above 90%, compatible with commercial capping enzymes and 2′-O-methyltransferases. DMF filing support available
Cap1 capping system (Cat. No. HBP001513)	Vaccinia Capping Enzyme, Cap 2′-O-Methyltransferase, SAM, GTP, RNase inhibitor and buffer in one kit. Produces Cap 0 or Cap 1 from uncapped RNA, with above 95% capping efficiency for standard sequences. Caps 50 µg RNA per reaction and scales to milligram level

The capping enzymes and SAM are produced under GMP-compliant conditions in an animal-origin-free process, with DMF filing support available.

Whichever analog you choose, check the template start-sequence requirement on its datasheet, because a transcript start that does not match the analog lowers capping efficiency.

Stage 4: Purification and quality control

After transcription and capping, the product needs to be separated from enzymes, template DNA, free nucleotides and truncated or double-stranded byproducts. Common approaches include precipitation, silica-based cleanup, oligo-dT affinity capture and chromatography, chosen according to scale and quality requirements.

A basic QC panel for IVT mRNA usually covers:

• Integrity and size: capillary electrophoresis or gel electrophoresis.

• Concentration and purity: spectrophotometry or fluorometry.

• dsRNA content: antibody-based dot blot or ELISA.

• Capping efficiency: LC-MS based methods.

• Residual template DNA and endotoxin: especially for in vivo use.

Stage 5: Delivery with lipid nanoparticles

Naked mRNA is fragile and does not enter cells efficiently. Lipid nanoparticles (LNPs), built from an ionizable lipid, a helper lipid, cholesterol and a PEG-lipid, protect the mRNA and carry it into cells. The best formulation depends on where you want the mRNA to go, so match the LNP to your experiment.

If your experiment is…	Consider
In vitro transfection of common mammalian cell lines	Fast LNP (in vitro, general), Cat. No. HBP003506
Primary cells, which are often more sensitive and harder to transfect	Fast LNP (in vitro, primary cell), Cat. No. HBP003508
Systemic delivery in animal models	Fast LNP (in vivo, system delivery), Cat. No. HBP003505
Delivery aimed at the lung	Fast LNP (in vivo, lung targeted), Cat. No. HBP003510

Tissue targeting depends on LNP composition and the animal model, so validate it in your own system, for example with a luciferase reporter mRNA and imaging.

What the Fast LNP range offers

• Ready to use: mix the LNP with your mRNA. The in vivo and lung-targeted formats encapsulate mRNA in about 1 minute, with no microfluidic instrument and no extra purification or buffer exchange.

• Low-input friendly: works with microgram-level mRNA amounts, and the in vivo format has zero dead volume, which helps when RNA is limited.

• Ethanol-free: the in vivo and lung-targeted formulations contain no ethanol components.

• In vivo (system delivery): mouse studies show systemic expression and delivery across multiple organs. Supplied for storage at −85 to −65 °C, and formed mRNA-LNP particles stay stable at 2–8 °C for up to 35 days.

• Lung targeted: mouse studies show preferential mRNA delivery and expression in lung tissue.

• In vitro (general): broad mammalian cell compatibility, with dose-dependent expression shown across cell types.

• In vitro (primary cell): designed for challenging primary cells and compatible with low-input experiments.

Stage 6: Validate with reporter and functional mRNA

Before running a precious sample, confirm that the workflow works with a control mRNA. Reporter mRNAs such as eGFP, Fluc (firefly luciferase) and mCherry give a quick readout of translation and delivery by fluorescence or luminescence. For functional studies, mRNAs such as Cas9 (genome editing), EPO, IL-12, OVA and cre cover common in vivo and immunology applications, and self-amplifying RNA (saRNA) is available for work that needs longer expression.

Research mRNAs are available in both unmodified and modified forms. Use the modified form when you want lower immunogenicity and stronger expression, particularly in primary cells and in vivo.

Troubleshooting the mRNA workflow

Symptom	Likely causes	What to check
Low IVT yield	Impure or degraded template; magnesium and pyrophosphate imbalance; poor nucleotide quality; inactive enzyme	Template purity and concentration; add pyrophosphatase; optimize magnesium; use fresh nucleotides and enzyme
Smeared bands or longer-than-expected products	Incomplete linearization; run-on transcription; RNase contamination	Verify digestion on a gel; use a Type IIS enzyme to define the template end; use RNase-free technique and an RNase inhibitor
Strong innate immune response or poor expression in cells	dsRNA byproducts; unmodified uridine; incomplete purification	Switch to a Low dsRNA or Thermostable T7; use modified UTP; add or improve purification; measure dsRNA
Weak translation despite good RNA integrity	Low capping efficiency; short or missing poly(A); delivery problem	Check capping efficiency and poly(A) design; consider Cap1; confirm delivery with a reporter mRNA
Poor LNP performance	Formulation not matched to cell type or tissue; compromised RNA quality	Choose the LNP type for the application; confirm RNA integrity before formulation; test with a reporter

Why source the workflow from one supplier

IVT, capping and delivery reagents all have to work together. Sourcing them from a single supplier simplifies qualification, documentation and technical support, and makes it easier to troubleshoot when something goes wrong, because there is one place to ask.

What HZYMES brings to that approach:

• GMP-compliant manufacturing: the T7 RNA polymerases, capping enzymes, SAM and cap analogs are produced under GMP-compliant quality systems, with traceability of the production process and of raw and auxiliary materials.

• Animal-origin-free processes: the enzymes are made without animal-derived materials, ampicillin or other β-lactam antibiotics.

• Controlled impurities and consistency: residual nucleases, RNase, endotoxin, host cell DNA and protein, and metal ions are controlled to support batch-to-batch consistency.

• Regulatory support: DMF filing support is available for the capping enzymes, SAM and cap analogs.

• Flexible supply: a complete range of mRNA capping reagents, with customized specifications and packaging available.

Frequently asked questions

What is in vitro transcription (IVT) in mRNA production?

IVT is the cell-free enzymatic synthesis of RNA from a DNA template. T7 RNA polymerase reads a linearized template that carries a T7 promoter and builds the RNA from nucleotide triphosphates. The resulting RNA is then capped, purified and delivered into cells.

Why does dsRNA matter in IVT mRNA?

dsRNA byproducts are recognized by innate immune sensors such as RIG-I, MDA5 and PKR. This can reduce protein expression and trigger inflammatory responses. Using a low-dsRNA or thermostable polymerase, modified nucleotides and good purification all help to limit it.

Should I use co-transcriptional or enzymatic capping?

Co-transcriptional capping is simpler and fits a one-pot process, as long as the template start sequence matches the cap analog. Enzymatic capping adds a step but is flexible and works on any uncapped RNA. Both can deliver a Cap1 structure.

Why use N1-methylpseudouridine instead of uridine?

N1-methylpseudouridine lowers recognition by innate immune sensors and can increase translation compared with unmodified uridine. It is used in approved COVID-19 mRNA vaccines and is a common choice for therapeutic-oriented mRNA.

How do I choose an LNP for my experiment?

Start from your target: common cell lines, primary cells, systemic delivery in animals, or lung. Pick the LNP designed for that use, and test it with a reporter mRNA such as Fluc or eGFP before moving to your mRNA of interest.

Talk to the HZYMES team

Request a quote, ask for a sample, or download the mRNA product catalog. Our technical team can help you choose the right components for your workflow.

[ Request Quote | Request Sample | Technical Support | Catalog download]